NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England
Industry Has Mixed Response To “Largest And Most Comprehensive Review”
Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.
You may also be interested in...
Companies are keen to know how the disease severity modifier and a more flexible approach to uncertainty will be applied to health technology appraisals for drugs in practice. They also want reassurance that there will be consistency in deliberations by NICE’s various committees and advisory groups.
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.
PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.